The Court of Appeal in Paris has ruled that Sanofi must pay 150.7 million euros to CNAM as compensation for anti-competitive practices related to the drug Plavix.
Matei Gaginsky
International
Foto: Sylvain ROBIN / Alamy / Profimedia
Always see our news on Google
The court's decision is based on a ruling from 2013, when Sanofi was fined 40.6 million euros for actions against generic drug manufacturers. The court found that the impact of these practices persisted until 2021, although the anti-competitive behavior lasted only five months. CNAM will receive 126.2 million euros for reimbursements and fees, plus 24.5 million euros in damages. Sanofi is reviewing the ruling and considers the possibility of an appeal to the Supreme Court.
Sources
Latest News
18:54
Record number of members expelled from the Chinese Communist Party
18:44
Two people died and one was injured after a rock formation collapsed in Göreme, Turkey
18:43
Barack Obama criticizes the Trump administration / The former president accuses the White House of “bowing” before Russian President Vladimir Putin and of “betraying the Ukrainians”
18:35
Ten sailors have been stranded for four months on the abandoned vessel in the Port of Constanța
18:25
Luca Niculescu and Mark Rutte discussed security in the Black Sea and hybrid threats on the eastern flank
See more news
NEWS ON THE SAME TOPICS
International
Germany will provide €400 million to maintain Sanofi’s insulin production and reduce the risk of shortages in Europe
International
Poland contests the ruling of the Brussels Tribunal to pay 1.3 billion euros for the Pfizer vaccines
Current Affairs
Fine of 9.91 million lei for Albalact. The court definitively ruled in favor of the Competition Council
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
